We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immupharma Plc (IMM) Ordinary 1p

Sell:2.88p Buy:3.19p 0 Change: 0.1p (3.12%)
Market closed |  Prices as at close on 15 January 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.88p
Buy:3.19p
Change: 0.1p (3.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 15 January 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.88p
Buy:3.19p
Change: 0.1p (3.12%)
Market closed |  Prices as at close on 15 January 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

Contact details

Address:
One Bartholomew Close
LONDON
EC1A 7BL
United Kingdom
Telephone:
+44 (020) 71524080
Website:
https://www.immupharma.co.uk/

Important dates

Future events
There are no future events available.
Past events
Interim results 09 September 2024 09/09/24
AGM 28 June 2024 28/06/24
Annual report 05 June 2024 05/06/24
Final results 05 June 2024 05/06/24

General stock information

EPIC:
IMM
ISIN:
GB0033711010
Market cap:
£12.91 million
Shares in issue:
416.44 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Timothy Mccarthy
    Executive Chairman of the Board, Chief Executive Officer
  • Ward Williams
    Chief Financial Officer, Company Secretary
  • Timothy Franklin
    Chief Operating Officer, Executive Director
  • Ashley Clarke
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.